Condoliase
| Clinical data | |
|---|---|
ECHA InfoCard | 100.029.785 |
| Chemical and physical data | |
| Formula | C5039H7770N1360O1525S22 |
| Molar mass | 112508.90 g·mol−1 |
Condoliase (Hernicore) is a
lumbar disc herniation. Clinical trials have shown its benefit in alleviation lumbar disc herniation associated low back pain and disability, although some concerns have been suggested with regard to promotion of disc degeneration.[1][2]
Condoliase is derived from the enzyme mucopolysaccharidase from the Gram-negative bacteria Proteus vulgaris.[3][4] It is an enzyme that specifically degrades glycosaminoglycans.[5][6][4]
It was approved for use in Japan in 2018.[7]
References
- PMID 36143959.
- PMID 36872214.
- PMID 36203868.
- ^ S2CID 24111394.
- .
- PMID 29424676.
- ^ "Seikagaku Announces New Drug Application Approval of HERNICORE 1.25 Units for Intradiscal Injection in Japan, Indicated for Treatment of Lumbar Disc Herniation". Seikagaku Corp (Press release). 23 March 2018 – via Reuters.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |